Copyright 2008 Medical News Today Latest Prostate / Prostate Cancer News From Medical News Today. http://www.medicalnewstoday.com/sections/prostate/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Sat, 19 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/115285.php UroToday.com - In this online publication by Dr. Alberto Briganti and associates that appears in European Urology, the authors hypothesized that surgical volume (SV) is related to the detection rate of lymph node invasion (LNI) in a single-institution cohort of men treated with radical prostatectomy (RP) and extended pelvic lymph node dissection (ePLND). Sat, 19 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/115283.php UroToday.com - In the online version of the BJU International, a group of Korean investigators has reported on the impact of liver function and lipid parameters on PSA levels. The liver is involved in eliminating serum PSA, but the kidneys and lungs are not. Free PSA is eliminated by the kidneys, but due to its molecular size, PSA bound to larger proteins is cleared through the liver. Furthermore, the lipid profile can affect serum PSA levels through the metabolism of serum testosterone. Thu, 17 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/115293.php Dendreon Corporation (Nasdaq: DNDN) announced that the Company has initiated a Phase 2 trial of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active cellular immunotherapy for the treatment of prostate cancer, in men with localized prostate cancer who are scheduled to undergo a radical prostatectomy. Thu, 17 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/115249.php Researchers at The University of Nottingham have shown an association between certain past diagnostic radiation procedures and an increased risk of young-onset prostate cancer - a rare form of prostate cancer which affects about 10 per cent of all men diagnosed with the disease. Tue, 15 Jul 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/114954.php Drugmaker Amgen Inc announced yesterday, Monday, that a large trial of its bone drug denosumab increased bone density and cut fractures in men with non-metastatic prostate cancer who were having hormone blocking therapy. A side effect of androgen deprivation therapy (ADT), which stops the male hormones feeding the cancer, is weaker bones and increased risk of fracture. Tue, 15 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/114998.php The Prostate Cancer Charity is supporting four new research projects across the UK. The projects, totaling over £500,000, aim to increase scientific understanding of prostate cancer and benefit current and future generations of men affected by the disease and their partners and families. Tue, 15 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/114956.php Amgen (NASDAQ: AMGN) announced findings from a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer. Mon, 14 Jul 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/114891.php Theragenics Corporation, a medical device Company serving the prostate cancer and surgical markets (NYSE: TGX), is challenging men to engage in a national debate surrounding the treatment of the disease that will affect one in six of them - prostate cancer. This week, the Company announced its latest campaign to promote awareness of proven prostate cancer treatment options, "The Great Prostate Debate. Sun, 13 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114807.php UroToday.com - With PSA screening, men are being diagnosed with prostate cancer (CaP) at younger ages. In the online issue of the BJU International, Dr. Steinsvik and colleagues address the issues of fertility as related to prostate cancer therapies. In Norway, the percentage of patients aged Sun, 13 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114806.php UroToday.com - In Prostate Cancer and Prostatic Diseases, a group from Palermo, Italy report on the use of antibiotics in patients with an elevated PSA. The study cohort consisted of 94 Caucasian men with a PSA between 4 and 10ng/ml, no symptoms of prostatitis, a negative rectal exam for cancer and who were otherwise candidates for prostate biopsy. All patients had a negative urinalysis and at least 2 previous elevated PSA detections with no greater than a 10% increase. Sun, 13 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114805.php UroToday.com - In the May 10, 2008 issue of the Journal of Clinical Oncology, Dr. Jim Hu and associates report on minimally invasive radical prostatectomy (MIRP). Using a 5% sampling of Medicare beneficiaries, 2,702 men undergoing MIRP and open RP from 2003-2005 were identified. Variables assessed included perioperative complications, length of hospital stay, anastomotic strictures, and initiation of salvage therapies. During this 2 year span, MIRP increased from 12.2% to 31. Sun, 13 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114804.php UroToday.com - In the June 18, 2008 edition of JAMA, Dr. Bruce Trock and associates reported on prostate cancer (CaP) specific survival following salvage radiotherapy (XRT) vs. observation in men with biochemical recurrence after radical prostatectomy (RP). They found a benefit to salvage XRT. Between 1982 and 2004, 926 men developed CaP recurrence following RP with staging pelvic lymphadenectomy at Johns Hopkins Hospital. Fri, 11 Jul 2008 10:00:00 PDT http://www.medicalnewstoday.com/articles/114542.php Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using Positron Emission Tomography (PET), to locate the diseased cells as they spread to the lymph nodes, the first place prostate cancer goes before invading other organs. The tiny cancer metastases in the pelvic lymph nodes are very difficult to find using conventional imaging tools such as CT scanning. Fri, 11 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/114621.php In the June 18, 2008 edition of JAMA, Dr. Bruce Trock and associates reported on prostate cancer (CaP) specific survival following salvage radiotherapy (XRT) vs. observation in men with biochemical recurrence after radical prostatectomy (RP). They found a benefit to salvage XRT. Between 1982 and 2004, 926 men developed CaP recurrence following RP with staging pelvic lymphadenectomy at Johns Hopkins Hospital. Thu, 10 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114428.php Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research. Philip M. Arlen, M.D. Wed, 09 Jul 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/114383.php Deaths due to the four most common cancers - lung, colorectal, prostate, and breast - have dropped substantially in the United States from 1993 to 2001 in working-aged individuals. However, not all Americans are equally likely to benefit from those gains. Wed, 09 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/114319.php New research to be published in tomorrow's issue of JAMA (Vol. 300, No. 2) by a team of investigators at The Cancer Institute of New Jersey (CINJ), shows a lack of survival benefit for older men with localized prostate cancer when administered a common therapy. At focus is a treatment known as androgen deprivation therapy, which shuts off male hormones known to promote growth of the disease. Wed, 09 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114023.php An article published in the July 9 issue of JAMA finds that elderly men with localized prostate cancer had no improvement in survival when treated with a therapy that deprives the prostate gland of androgen (a male hormone) compared to conservative management of the disease. Among men, prostate cancer is the most common cancer after skin cancer and is the second leading cause of cancer deaths after lung cancer. Tue, 08 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/114153.php Light Sciences Oncology, Inc. (LSO) today announced that it has begun treatment of patients with benign prostatic hyperplasia (BPH), or enlargement of the prostate, using Light Infusion Therapy(TM) (Litx(TM)), an innovative light-activated drug treatment under development. LSO plans to conduct a 12-patient, Phase I/I I dose-escalation study at four sites in the United States as well as a 40-patient, Phase IIa study in Australia, expected to begin during the current quarter. Mon, 07 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/114080.php Counting the number of tumor cells circulating in the bloodstream of patients with castration-resistant prostate cancer can accurately predict how well they are responding to treatment, new results show. At the ESMO Conference Lugano (ECLU) organized by the European Society for Medical Oncology, researchers showed that changes in the number of circulating tumor cells predicted the outcome after chemotherapy in this hard to treat cancer. Sun, 06 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/114078.php ORLANDO, FL (UroToday.com) - (Reported from the Annual Meeting of the American Urological Association) Three studies showed that surgical skills training for robot assisted laparoscopic prostatectomy (RALP) for residents and fellows can be done effectively with no adverse impact on patient outcomes. Sun, 06 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/114077.php ORLANDO, FL (UroToday.com) - Canadian investigators created a teaching and mentoring method called "block" surgery to simplify and improve time efficiency and safety while maintaining acceptable oncological and functional outcomes during the learning curve of a laparoscopic radical prostatectomy (LRP). The LRP was broken down into 10 key "blocks" assigned different levels of difficulty. Practicing urologists were recruited from multiple centers. Sat, 05 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113914.php ORLANDO, FL (UroToday.com) - (Reported from the Annual Meeting of the American Urological Association) Abstract 996 and 1001 compared laparoscopic and open radical prostatectomy. There was little to no difference in blood loss, hospital stay, continence, and potency. The 5-year disease-free survival rates for laparoscopic radical prostatectomy are shown below. Wed, 02 Jul 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/113574.php ORLANDO, FL (UroToday.com) - Highlights of the advance prostate cancer session included; effectiveness of salvage radiation therapy for a rising PSA after radical prostatectomy, role of an extended lymph node dissection, dutesteride for rising PSA, use of anti-PSMA monoclonal antibodies for hormone-refractory prostate cancer, and long-term side effects of androgen deprivation. Abstract 522 evaluated men with a rising PSA after radical prostatectomy. Wed, 02 Jul 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/113573.php ORLANDO, FL (UroToday.com) - There were many interesting presentations this year. Highlights included PSA follow-up protocols after radical prostatectomy, predictors of incontinence after prostate surgery, adjuvant radiation therapy, and high-intensity frequency ultrasound for the treatment of focal prostate cancer.